Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With COVID-19: Implications From Clinical Features to Pathologic Findings

Circulation. 2020 Jun 2;141(22):1736-1738. doi: 10.1161/CIRCULATIONAHA.120.046988. Epub 2020 Apr 16.

Authors

Xin Zhou¹, Yongle Li¹, Qing Yang¹

Affiliation

¹ Department of Cardiology, Tianjin Medical University General Hospital, China.

PMID: 32298134
DOI: 10.1161/CIRCULATIONAHA.120.046988

No abstract available

Keywords: COVID-19; coronavirus.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acute Coronary Syndrome / complications
Acute Coronary Syndrome / drug therapy*
Acute Coronary Syndrome / pathology
Betacoronavirus / isolation & purification
COVID-19
Coronavirus Infections / complications
Coronavirus Infections / pathology*
Coronavirus Infections / virology
Disease Progression
Hemorrhage / etiology
Humans
Lung / pathology
Pandemics
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Count
Pneumonia, Viral / complications
Pneumonia, Viral / pathology*
Pneumonia, Viral / virology
SARS-CoV-2

Substances

Platelet Aggregation Inhibitors